Literature DB >> 17004113

A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches.

Janet E Olson1, James N Ingle, Cynthia X Ma, Linda L Pelleymounter, Daniel J Schaid, V Shane Pankratz, Robert A Vierkant, Zachary S Fredericksen, Yanhong Wu, Fergus J Couch, Celine M Vachon, Thomas A Sellers, Richard M Weinshilboum.   

Abstract

BACKGROUND: Numerous studies point to a positive relationship between elevated levels of estrogens and increased risk of breast. Androgens are converted to estrogens by the aromatase enzyme, which is encoded by the CYP19 gene. We recently published resequencing data on 88 polymorphisms identified in that gene. The hypothesis tested in this study was that polymorphisms, or haplotypes, in CYP19 are related to risk of breast cancer.
METHODS: Incident cases of breast cancer were identified through the Division of Medical Oncology at the Mayo Clinic in Rochester, MN. Controls were patients visiting Mayo for an annual medical examination. Controls were frequency matched to cases based on age and region of residence. Tag-polymorphisms were selected using 2 methods: (1) 12 variants using the tag-selection method of Carlson et al. (Am J Hum Genet 74:106-120, 2004); and (2) 12 variants using the haplotype method of Stram (Genet Epidemiol 27:365-374, 2004). Six SNPs were selected by both methods. Genotyping was conducted using SNPStream, TaqMan and RFLP analyses. Logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI). Analyses were conducted among all cases and controls, or stratified by estrogen receptor alpha (ER) status and/or menopausal status.
RESULTS: A total of 750 cases (60% postmenopausal) and 732 controls (75% postmenopausal) were included. No association with breast cancer risk was detected for individual variants, selected tagSNPs or hap-tag SNPs despite 80% power to detect OR as low as 1.49 for minor allele frequency (MAF) of 0.10. Similarly, stratified analyses based on ER status or menopausal status failed to detect any association with breast cancer risk.
CONCLUSION: These analyses suggest that variants of CYP19 are not associated with risk of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17004113      PMCID: PMC2868324          DOI: 10.1007/s10549-006-9324-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  23 in total

Review 1.  Estrogen and the risk of breast cancer.

Authors:  M Clemons; P Goss
Journal:  N Engl J Med       Date:  2001-01-25       Impact factor: 91.245

2.  High-throughput multiplex single-nucleotide polymorphism analysis for red cell and platelet antigen genotypes.

Authors:  G A Denomme; M Van Oene
Journal:  Transfusion       Date:  2005-05       Impact factor: 3.157

Review 3.  Estrogen carcinogenesis in breast cancer.

Authors:  James D Yager; Nancy E Davidson
Journal:  N Engl J Med       Date:  2006-01-19       Impact factor: 91.245

4.  Aromatase and breast cancer susceptibility.

Authors:  N M Probst-Hensch; S A Ingles; A T Diep; R W Haile; F Z Stanczyk; L N Kolonel; B E Henderson
Journal:  Endocr Relat Cancer       Date:  1999-06       Impact factor: 5.678

5.  Aromatase inhibitors for therapy of advanced breast cancer.

Authors:  James N Ingle; Vera J Suman
Journal:  J Steroid Biochem Mol Biol       Date:  2005-05       Impact factor: 4.292

6.  Genetic variants of CYP19 (aromatase) and breast cancer risk.

Authors:  V N Kristensen; N Harada; N Yoshimura; E Haraldsen; P E Lonning; B Erikstein; R Kåresen; T Kristensen; A L Børresen-Dale
Journal:  Oncogene       Date:  2000-03-02       Impact factor: 9.867

7.  Polymorphic variation in CYP19 and the risk of breast cancer.

Authors:  S W Baxter; D Y Choong; D M Eccles; I G Campbell
Journal:  Carcinogenesis       Date:  2001-02       Impact factor: 4.944

Review 8.  Estrogens as endogenous genotoxic agents--DNA adducts and mutations.

Authors:  E Cavalieri; K Frenkel; J G Liehr; E Rogan; D Roy
Journal:  J Natl Cancer Inst Monogr       Date:  2000

9.  A tetranucleotide repeat polymorphism in CYP19 and breast cancer risk.

Authors:  C A Haiman; S E Hankinson; D Spiegelman; I De Vivo; G A Colditz; W C Willett; F E Speizer; D J Hunter
Journal:  Int J Cancer       Date:  2000-07-15       Impact factor: 7.396

10.  Adjuvant endocrine therapy for postmenopausal women with early breast cancer.

Authors:  James N Ingle
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

View more
  19 in total

1.  Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium.

Authors:  Veronica Wendy Setiawan; Jennifer A Doherty; Xiao-Ou Shu; Mohammad R Akbari; Chu Chen; Immaculata De Vivo; Angela Demichele; Montserrat Garcia-Closas; Marc T Goodman; Christopher A Haiman; Susan E Hankinson; Brian E Henderson; Pamela L Horn-Ross; James V Lacey; Loic Le Marchand; Douglas A Levine; Xiaolin Liang; Jolanta Lissowska; Galina Lurie; Monica McGrath; Steven A Narod; Timothy R Rebbeck; Giske Ursin; Noel S Weiss; Yong-Bing Xiang; Hannah P Yang; Wei Zheng; Sara H Olson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

2.  The impacts of the interaction of genetic variation, CYP11β2 and NEDD4L, with sodium intake on pediatric obesity with gender difference: a 3-year panel study.

Authors:  M Lee; D Y Kwon; J Park
Journal:  Int J Obes (Lond)       Date:  2016-12-26       Impact factor: 5.095

Review 3.  Androgens and the breast.

Authors:  Constantine Dimitrakakis; Carolyn Bondy
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

4.  Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.

Authors:  Fiona M Blows; Kristy E Driver; Marjanka K Schmidt; Annegien Broeks; Flora E van Leeuwen; Jelle Wesseling; Maggie C Cheang; Karen Gelmon; Torsten O Nielsen; Carl Blomqvist; Päivi Heikkilä; Tuomas Heikkinen; Heli Nevanlinna; Lars A Akslen; Louis R Bégin; William D Foulkes; Fergus J Couch; Xianshu Wang; Vicky Cafourek; Janet E Olson; Laura Baglietto; Graham G Giles; Gianluca Severi; Catriona A McLean; Melissa C Southey; Emad Rakha; Andrew R Green; Ian O Ellis; Mark E Sherman; Jolanta Lissowska; William F Anderson; Angela Cox; Simon S Cross; Malcolm W R Reed; Elena Provenzano; Sarah-Jane Dawson; Alison M Dunning; Manjeet Humphreys; Douglas F Easton; Montserrat García-Closas; Carlos Caldas; Paul D Pharoah; David Huntsman
Journal:  PLoS Med       Date:  2010-05-25       Impact factor: 11.069

5.  A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.

Authors:  Zaida Garcia-Casado; Angel Guerrero-Zotano; Antonio Llombart-Cussac; Ana Calatrava; Antonio Fernandez-Serra; Amparo Ruiz-Simon; Joaquin Gavila; Miguel A Climent; Sergio Almenar; Jose Cervera-Deval; Josefina Campos; Carlos Vazquez Albaladejo; Antonio Llombart-Bosch; Vicente Guillem; Jose A Lopez-Guerrero
Journal:  BMC Cancer       Date:  2010-02-09       Impact factor: 4.430

6.  Associations between CYP19A1 polymorphisms, Native American ancestry, and breast cancer risk and mortality: the Breast Cancer Health Disparities Study.

Authors:  Stephanie D Boone; Kathy B Baumgartner; Richard N Baumgartner; Avonne E Connor; Christina M Pinkston; Shesh N Rai; Elizabeth C Riley; Lisa M Hines; Anna R Giuliano; Esther M John; Mariana C Stern; Gabriela Torres-Mejía; Roger K Wolff; Martha L Slattery
Journal:  Cancer Causes Control       Date:  2014-08-05       Impact factor: 2.506

7.  Survival prediction based on inherited gene variation analysis.

Authors:  Mine S Cicek; Matthew J Maurer; Ellen L Goode
Journal:  Methods Mol Biol       Date:  2013

8.  Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms.

Authors:  Yuan Ji; Janet Olson; Jianping Zhang; Michelle Hildebrandt; Liewei Wang; James Ingle; Zachary Fredericksen; Thomas Sellers; William Miller; J Michael Dixon; Hiltrud Brauch; Michel Eichelbaum; Christina Justenhoven; Ute Hamann; Yon Ko; Thomas Brüning; Jenny Chang-Claude; Shan Wang-Gohrke; Daniel Schaid; Richard Weinshilboum
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

9.  Haplotype analyses of CYP19A1 gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study.

Authors:  Qiuyin Cai; Nobuhiko Kataoka; Chun Li; Wanqing Wen; Jeffrey R Smith; Yu-Tang Gao; Xiao Ou Shu; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-01       Impact factor: 4.254

10.  Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China.

Authors:  Chu Chen; Lori C Sakoda; Jennifer A Doherty; Melissa M Loomis; Sherianne Fish; Roberta M Ray; Ming Gang Lin; Wenhong Fan; Lue Ping Zhao; Dao Li Gao; Helge Stalsberg; Ziding Feng; David B Thomas
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-12       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.